Affordable Access

Access to the full text

Sitagliptin: a potential drug for the treatment of COVID-19?

Authors
  • Bardaweel, Sanaa K.1
  • Hajjo, Rima2
  • Sabbah, Dima A.2
  • 1 University of Jordan, 11942 , (Jordan)
  • 2 Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733 , (Jordan)
Type
Published Article
Journal
Acta Pharmaceutica
Publisher
Sciendo
Publication Date
Nov 04, 2020
Volume
71
Issue
2
Pages
175–184
Identifiers
DOI: 10.2478/acph-2021-0013
Source
De Gruyter
Keywords
License
Green

Abstract

Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.

Report this publication

Statistics

Seen <100 times